Industry-Academic Cooperation Foundation, Yonsei University of Yonsei University

Republic of Korea

Back to Profile

1-1 of 1 for Industry-Academic Cooperation Foundation, Yonsei University of Yonsei University Sort by
Query
Aggregations
IPC Class
A61K 31/47 - QuinolinesIsoquinolines 1
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine 1
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid 1
C07D 207/00 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom 1
C07D 215/00 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems 1
See more
Found results for  patents

1.

TRIAZINE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST ACETYL-COA CARBOXYLASE

      
Application Number KR2007006192
Publication Number 2008/072850
Status In Force
Filing Date 2007-12-03
Publication Date 2008-06-19
Owner
  • AMOREPACIFIC CORPORATION (Republic of Korea)
  • CRYSTALGENOMICS, INC. (Republic of Korea)
  • INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY of Yonsei University (Republic of Korea)
Inventor
  • Joo, Yung Hyup
  • Kang, Seung-Hyun
  • Hong, Yong Deog
  • Kim, Yeonjoon
  • Byoun, Kyounghee
  • Woo, Byoung Young
  • Park, Miyoung
  • Ha, Jun Yong
  • Koh, Hyunju
  • Lim, Kyung Min
  • Kim, Chae-Wook
  • Lee, Byoung-Seok
  • Kim, Jung Ju
  • Jang, Doo Ok
  • Tae, Jinsung
  • Shin, Dongkyu
  • Kim, Yong Eun
  • Lee, Kyung Ho
  • Lee, Jae Il
  • Hyun, Young-Lan
  • Ro, Seonggu
  • Cho, Joong Myung

Abstract

The present invention relates to a novel triazine derivative or a pharmaceutically acceptable salt thereof, and an Acetyl-CoA Carboxylase (ACC) comprising same as an active ingredient. The triazine derivative of the present invention effectively inhibits the activity of ACC and it may be used for preventing or treating obesity, diabetes, dyslipidemia and diseases related to metabolic syndrome.

IPC Classes  ?

  • C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
  • C07D 251/72 - Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
  • C07D 251/02 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
  • C07D 215/00 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D 265/00 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
  • C07D 207/00 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D 221/00 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups
  • A61K 31/47 - QuinolinesIsoquinolines
  • A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
  • A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid